<DOC>
	<DOC>NCT02483533</DOC>
	<brief_summary>LIPO-202-CL-23 is a follow-on study to evaluate the post-treatment safety and duration of clinical effect of LIPO-202 in subjects that completed either the LIPO-202-CL-18 or LIPO-202-CL-19 (parent studies). No risks related to treatment are anticipated as subjects will not receive additional treatment with LIPO-202 or Placebo for LIPO-202 in this follow-on study.</brief_summary>
	<brief_title>Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202</brief_title>
	<detailed_description />
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Healthy male or nonpregnant female subjects who completed Study LIPO202CL18 or LIPO202CL19 Capable of providing written consent Willing to comply with the study procedures and schedule Female subjects who are pregnant or are not using adequate birth control methods Plan on starting a weight loss or exercise program during the study Plan to enroll in another investigational drug or device study Unlikely or unable to adhere to the study visit schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>